Related Experiment Video
Updated: Jun 15, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Dilated cardiomyopathy
John Lynn Jefferies1, Jeffrey A Towbin
1Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
Insights
Dilated cardiomyopathy involves enlarged heart ventricles and impaired pumping function, leading to heart failure and sudden death risks. Genetic factors and toxins contribute, necessitating improved treatment strategies for better patient outcomes.
Area of Science:
- Cardiology
- Genetics
- Pathophysiology
Background:
- Dilated cardiomyopathy (DCM) is defined by left ventricular dilation and systolic dysfunction.
- It can progress to diastolic dysfunction, right ventricular impairment, and heart failure.
- Patients face risks of arrhythmias, syncope, and sudden cardiac death.
Purpose of the Study:
- To summarize the key characteristics, causes, and management of dilated cardiomyopathy.
- To highlight the genetic and environmental factors contributing to DCM.
- To underscore the ongoing need for improved therapeutic outcomes.
Main Methods:
- Review of existing literature on dilated cardiomyopathy.
- Analysis of genetic and etiological factors.
- Summary of current treatment approaches and outcomes.
Main Results:
- DCM affects cardiac efficiency, with genetic factors in 30-48% of cases.
- Causes include cytoskeletal/sarcomeric protein gene mutations, toxins, and inflammation (e.g., myocarditis).
- In children, mitochondrial dysfunction and metabolic issues are implicated.
Conclusions:
- Current treatments aim to enhance cardiac efficiency and reduce mechanical stress.
- Arrhythmia management and sudden death prevention are critical.
- Despite advancements, improving patient outcomes in dilated cardiomyopathy remains a priority.
Abstract:
Dilated cardiomyopathy is characterised by left ventricular dilation that is associated with systolic dysfunction. Diastolic dysfunction and impaired right ventricular function can develop. Affected individuals are at risk of left or right ventricular failure, or both. Heart failure symptoms can be exercise-induced or persistent at rest. Many patients are asymptomatic. Chronically treated patients sometimes present acutely with decompensated heart failure. Other life-threatening risks are ventricular arrhythmias and atrioventricular block, syncope, and sudden death. Genetic inheritance arises in 30-48% of patients, and inflammatory disorders such as myocarditis or toxic effects from medications, alcohol, or illicit drugs also result in dilated cardiomyopathy. Genes that cause dilated cardiomyopathy generally encode cytoskeletal and sarcomeric (contractile apparatus) proteins, although disturbance of calcium homeostasis also seems to be important. In children, disrupted mitochondrial function and metabolic abnormalities have a causal role. Treatments focus on improvement of cardiac efficiency and reduction of mechanical stress. Arrhythmia therapy and prevention of sudden death continue to be mainstays of treatment. Despite progress over the past 10 years, outcomes need to be improved.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

